Jennifer Furin1. 1. Brigham and Women's Hospital, Division of Social Medicine and Health Inequalities, Harvard Medical School, Boston, Massachusetts 02120, USA. jfurin@partners.org
Abstract
PURPOSE OF REVIEW: Drug-resistant tuberculosis is a growing problem, with almost half a million cases worldwide. In spite of the difficulty in its management, drug-resistant tuberculosis can be successfully treated, even in poor settings. RECENT FINDINGS: This article will review key findings in the areas of epidemiology, diagnosis and management of drug-resistant tuberculosis, including new antituberculous drugs. The issue of extensively drug-resistant tuberculosis will also be reviewed and discussed. Finally, novel approaches to the management of drug-resistant tuberculosis in populations with HIV, as well as in pediatric populations, among pregnant women, and among patients requiring surgical therapy, will be reviewed. SUMMARY: New advances in the diagnosis and management of drug-resistant tuberculosis allow for excellent clinical outcomes to be achieved, even in difficult-to-treat populations. This is possible with timely diagnosis of disease and rapid initiation of appropriate therapy in supported settings.
PURPOSE OF REVIEW: Drug-resistant tuberculosis is a growing problem, with almost half a million cases worldwide. In spite of the difficulty in its management, drug-resistant tuberculosis can be successfully treated, even in poor settings. RECENT FINDINGS: This article will review key findings in the areas of epidemiology, diagnosis and management of drug-resistant tuberculosis, including new antituberculous drugs. The issue of extensively drug-resistant tuberculosis will also be reviewed and discussed. Finally, novel approaches to the management of drug-resistant tuberculosis in populations with HIV, as well as in pediatric populations, among pregnant women, and among patients requiring surgical therapy, will be reviewed. SUMMARY: New advances in the diagnosis and management of drug-resistant tuberculosis allow for excellent clinical outcomes to be achieved, even in difficult-to-treat populations. This is possible with timely diagnosis of disease and rapid initiation of appropriate therapy in supported settings.
Authors: N Alsaad; J A Dijkstra; O W Akkerman; W C M de Lange; D van Soolingen; J G W Kosterink; T S van der Werf; J W C Alffenaar Journal: Antimicrob Agents Chemother Date: 2016-06-20 Impact factor: 5.191
Authors: M D Morris; L Quezada; P Bhat; K Moser; J Smith; H Perez; R Laniado-Laborin; J Estrada-Guzman; T C Rodwell Journal: Int J Tuberc Lung Dis Date: 2013-07 Impact factor: 2.373